Lupin To Present Cancer Drug Data at ASCO 2025
27 May 2025
2 Min Read
CW Team
Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457鈥攁 novel PRMT5 inhibitor鈥攁t the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics鈥擬olecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.
LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.
The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.
Vinita Gupta, CEO of Lupin, commented, 鈥淲e are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.鈥�
Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.
Presentation Details:
4. Date: 2 June 2025
5. Time: 1:30鈥�4:30 pm CDT
6. Location: Hall A, McCormick Place, Chicago
7. Abstract No.: 3107 | Poster Board No.: 422
8. Trial Registration: CTRI/2023/07/054753
9. DOI: 10.1200/JCO.2025.43.16_suppl.3107
Lupin鈥檚 participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.
Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457鈥攁 novel PRMT5 inhibitor鈥攁t the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics鈥擬olecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.Vinita Gupta, CEO of Lupin, commented, 鈥淲e are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.鈥滾upin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.Presentation Details:4. Date: 2 June 20255. Time: 1:30鈥�4:30 pm CDT6. Location: Hall A, McCormick Place, Chicago7. Abstract No.: 3107 | Poster Board No.: 4228. Trial Registration: CTRI/2023/07/0547539. DOI: 10.1200/JCO.2025.43.16_suppl.3107Lupin鈥檚 participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.
Next Story
Ashwin Sheth Group Buys 50% Stake in One Marina
Mumbai-based real estate developer Ashwin Sheth Group has acquired a 50 per cent stake in the Rs 23 billion (USD 275 million) luxury residential project One Marina, located in South Mumbai鈥檚 upscale Marine Lines. The acquisition was announced on 11 June and marks a major move in the city's premium housing market.The stake was acquired from Vallabh Sheth and Jitendra Sheth, promoters of Sheth Creators, who previously co-owned the project along with YM Infra, the landowner. This acquisition was supported by a substantial USD 65 million (over Rs 5.4 billion) investment commitment from PAG Singa..
Next Story
96km Rail Line to Link Rajasthan's Sirohi to Network
In a major step towards improving infrastructure in Rajasthan, the central government has approved the final location survey for a 96-kilometre railway line connecting Marwar Bagra (Jalore)鈥揝irohi鈥揝warupganj, thereby integrating Sirohi district into the national railway network for the first time.The approval, announced on Monday, marks a long-awaited development for tribal-dominated western Rajasthan. Sirohi, currently without a rail link, lies near the important Delhi鈥揂jmer鈥揂bu Road鈥揂hmedabad corridor, while Jalore is already on the Samdari鈥揃hildi鈥揋andhidham route.Railway Minis..
Next Story
Push Grows for Berhampur-Sambalpur Rail Via Phulbani
A coalition of social organisations under the Milita Kriya Anusthan Committee has stepped up its campaign for the construction of a Berhampur鈥揝ambalpur (Rairkhol) railway line via Bhanjanagar and Phulbani, aiming to improve rail connectivity in southern Odisha.On Friday, the group launched a public awareness drive across Ganjam and Kandhamal districts, highlighting the urgent need for the proposed railway route. A "Vikash Rath" bus, carrying around 40 committee members, began its journey from the local railway station, stopping for public meetings in Hinjili, Aska, and Bhanjanagar, with a fo..
